Myricetin attenuated MPP +-induced cytotoxicity by anti-oxidation and inhibition of MKK4 and JNK activation in MES23.5 cells

Neuropharmacology

Volumn 61, Issue 1-2, 2011, Pages 329-335

  Zhang, Kai ^a   Ma, Zegang ^a   Wang, Jun ^a   Xie, Anmu ^a   Xie, Junxia ^a  

^a QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

MKK4; MPP +; Myricetin; Oxidative stress

Indexed keywords

CASPASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MYRICETIN; PROTEIN BAX; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTICLE; CELL DAMAGE; CELL LOSS; CELL NUCLEUS; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; MITOCHONDRIAL MEMBRANE POTENTIAL; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT;

1-METHYL-4-PHENYLPYRIDINIUM; ANTIOXIDANTS; CELLS, CULTURED; ENZYME ACTIVATION; FLAVONOIDS; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MAP KINASE KINASE 4; MEMBRANE POTENTIAL, MITOCHONDRIAL; PROTEIN KINASE INHIBITORS;

EID: 79957925598     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2011.04.021     Document Type: Article

References (34)

1. Anantharam, V., Lehrmann, E., Kanthasamy, A., Yang, Y., Banerjee, P., Becker, K.G., Freed, W.J., Kanthasamy, A.G., 2007. Microarray analysis of oxidative stress regulated genes in mesencephalic dopaminergic neuronal cells: relevance to oxidative damage in Parkinson's disease. Neurochem. Int. 50, 834-847.
2. Andersen, J.K., 2004. Iron dysregulation and Parkinson's disease. J. Alzheimers Dis. 6, S47-S52. (Pubitemid 40202542)
3. Cassarino, D.S., Parks, J.K., Parker Jr., W.D., Bennett Jr., J.P., 1999. The parkinsonian neurotoxin MPP+ opens the mitochondrial permeability transition pore and releases cytochrome c in isolated mitochondria via an oxidative mechanism. Biochim. Biophys. Acta 1453, 49-62.
4. Crawford Jr., G.D., Le,W.D., Smith, R.G., Xie,W.J., Stefani, E., Appel, S.H., 1992. A novel N18TG2 x mesencephalon cell hybrid expresses properties that suggest a dopaminergic cell line of substantia nigra origin. J. Neurosci. 12, 3392-3398.
5. Desai, V.G., Feuers, R.J., Hart, R.W., Ali, S.F., 1996. MPP(+)-induced neurotoxicity in mouse is age-dependent: evidenced by the selective inhibition of complexes of electron transport. Brain Res. 715, 1-8. (Pubitemid 26141647)
6. Gardoni, F., Di Luca, M., 2006. New targets for pharmacological intervention in the glutamatergic synapse. Eur. J. Pharmacol. 545, 2-10.
7. Grunblatt, E., Mandel, S., Jacob-Hirsch, J., Zeligson, S., Amariglo, N., Rechavi, G., Li, J., Ravid, R., Roggendorf, W., Riederer, P., et al., 2004. Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J. Neural Transm. 111, 1543-1573. (Pubitemid 40068786)
8. Hanasaki, Y., Ogawa, S., Fukui, S., 1994. The correlation between active oxygens scavenging and antioxidative effects of flavonoids. Free Radic. Biol. Med. 16, 845-850.
9. Herdegen, T., Waetzig, V., 2001. AP-1 p.oteins in the adult brain: facts and fiction about effectors of neuroprotection and neurodegeneration. Oncogene 20, 2424-2437. (Pubitemid 32531300)
10. Hladovec, J., 1977. Antithrombotic effects of some flavonoids alone and combined with acetylsalicylic acid. Arzneimittelforschung 27, 1989-1992. (Pubitemid 8169247)
11. Jenner, P., 2003. Oxidative stress in Parkinson's disease. Ann. Neurol. 53 (Suppl 3), S26-S36. Discussion S36-28.
12. Kang, K.A., Wang, Z.H., Zhang, R., Piao, M.J., Kim, K.C., Kang, S.S., Kim, Y.W., Lee, J., Park, D., Hyun, J.W., 2010. Myricetin protects cells against oxidative stressinduced apoptosis via regulation of PI3K/Akt and MAPK signaling pathways. Int. J. Mol. Sci. 11, 4348-4360.
13. Kidd, P.M., 2000. Parkinson's disease as multifactorial oxidative neurodegeneration: implications for integrative management. Altern. Med. Rev. 5, 502-529.
14. Kim, J.E., Kwon, J.Y., Lee, D.E., Kang, N.J., Heo, Y.S., Lee, K.W., Lee, H.J., 2009. MKK4 is a novel target for the inhibition of tumor necrosis factor-alpha-induced vascular endothelial growth factor expression by myricetin. Biochem. Pharmacol. 77, 412-421.
15. Koprich, J.B., Reske-Nielsen, C., Mithal, P., Isacson, O., 2008. Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease. J. Neuroinflammation 5, 8.
16. Lee, K.H., Choi, E.M., 2008. Myricetin, a naturally occurring flavonoid, prevents 2-deoxy-D-ribose induced dysfunction and oxidative damage in osteoblastic MC3T3-E1 cells. Eur. J. Pharmacol. 591, 1-6.
17. Linazasoro, G.J., 2002. Neuroprotection in Parkinson's disease: love story or mission impossible? Expert Rev. Neurother 2, 403-416. (Pubitemid 34627346)
18. Lotharius, J., Brundin, P., 2002. Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nat. Rev. Neurosci. 3, 932-942.
19. Ma, Z.G., Wang, J., Jiang, H., Liu, T.W., Xie, J.X., 2007. Myricetin reduces 6-hydroxydopamine-induced dopamine neuron degeneration in rats. Neuroreport 18, 1181-1185. (Pubitemid 46988076)
20. Mandel, S., Grunblatt, E., Youdim, M., 2000. cDNA microarray to study gene expression of dopaminergic neurodegeneration and neuroprotection in MPTP and 6-hydroxydopamine models: implications for idiopathic Parkinson's disease. J. Neural Transm. Suppl., 117-124.
21. McNaught, K.S., Belizaire, R., Jenner, P., Olanow, C.W., Isacson, O., 2002. Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease. Neurosci. Lett. 326, 155-158.
22. Moldzio, R., Radad, K., Duvigneau, J.C., Kranner, B., Krewenka, C., Piskernik, C., Rausch, W.D., 2006. Glutamate-induced cell death and formation of radicals can be reduced by lisuride in mesencephalic primary cell culture. J. Neural Transm. 113, 1095-1105. (Pubitemid 44291006)
23. Molina-Jimenez, M.F., Sanchez-Reus, M.I., Benedi, J., 2003. Effect of fraxetin and myricetin on rotenone-induced cytotoxicity in SH-SY5Y cells: comparison with N-acetylcysteine. Eur. J. Pharmacol. 472, 81-87.
24. Oltvai, Z.N., Milliman, C.L., Korsmeyer, S.J., 1993. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74, 609-619. (Pubitemid 23259742)
25. Ono, K., Yoshiike, Y., Takashima, A., Hasegawa, K., Naiki, H., Yamada, M., 2003. Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease. J. Neurochem. 87, 172-181. (Pubitemid 37210651)
26. Sanelli, T., Ge, W., Leystra-Lantz, C., Strong, M.J., 2007. Calcium mediated excitotoxicity in neurofilament aggregate-bearing neurons in vitro is NMDA receptor dependant. J. Neurol. Sci. 256, 39-51.
27. Shimmyo, Y., Kihara, T., Akaike, A., Niidome, T., Sugimoto, H., 2008. Multifunction of myricetin on A beta: neuroprotection via a conformational change of A beta and reduction of A beta via the interference of secretases. J. Neurosci. Res. 86, 368-377.
28. Thomas, T., Timmer, M., Cesnulevicius, K., Hitti, E., Kotlyarov, A., Gaestel, M., 2008. MAPKAP kinase 2-deficiency prevents neurons from cell death by reducing neuroinflammationerelevance in a mouse model of Parkinson's disease. J. Neurochem. 105, 2039-2052. (Pubitemid 351678515)
29. Van der Schyf, C.J., Geldenhuys, W.J., Youdim, M.B., 2006. Multifunctional drugs with different CNS targets for neuropsychiatric disorders. J. Neurochem. 99, 1033-1048. (Pubitemid 44655271)
30. Xia, X.G., Harding, T., Weller, M., Bieneman, A., Uney, J.B., Schulz, J.B., 2001. Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease. Proc. Natl. Acad. Sci. U S A 98, 10433-10438.
31. Xu, H.M., Jiang, H., Wang, J., Luo, B., Xie, J.X., 2008. Over-expressed human divalent metal transporter 1 is involved in iron accumulation in MES23.5 cells. Neurochem. Int. 52, 1044-1051.
32. Youdim, M.B., Buccafusco, J.J., 2005. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol. Sci. 26, 27-35.
33. Zhang, S., Wang, J., Song, N., Xie, J., Jiang, H., 2009. Up-regulation of divalent metal transporter 1 is involved in 1-methyl-4-phenylpyridinium (MPP(+))-induced apoptosis in MES23.5 cells. Neurobiol. Aging 30, 1466-1476.
34. Zhu, H.J., Liu, G.Q., 2004. Glutamate up-regulates P-glycoprotein expression in rat brain microvessel endothelial cells by an NMDA receptor-mediated mechanism. Life Sci. 75, 1313-1322.